Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00710905|
Recruitment Status : Terminated (Postmarket study terminated as the SN6AD3 is no longer promoted.)
First Posted : July 8, 2008
Results First Posted : November 8, 2011
Last Update Posted : November 24, 2011
|Condition or disease||Intervention/treatment||Phase|
|Cataract||Device: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||September 2010|
|Actual Study Completion Date :||September 2010|
Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
Device: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3
Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
- Binocular Visual Acuity at Near, Intermediate and Distance [ Time Frame: 6 months after surgery ]Binocular uncorrected and best corrected visual acuity (VA) was tested at 4 meters (m) (distance), 60 centimeters (cm) (intermediate), and near at preferred distance (distance chosen by each subject and recorded in cm; mean and standard deviation calculated) with a standard ETDRS chart for distance and a hand held chart for near. Scores were calculated using logMAR values. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better VA.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00710905
|Canada, British Columbia|
|Dr John Blaylock|
|Abbotsford, British Columbia, Canada, V2S 5A1|
|Dr Dominique Meyer|
|Quebec City, Quebec, Canada, G1S 1X6|
|Principal Investigator:||John Blaylock|